Publications

How minimally invasive liquid biopsy technologies can guide safer, more targeted treatment.

Identifying molecular markers to better predict treatment response and support more precise, personalised clinical decision-making for children with high-risk cancers.

An overview of the initial safety and tolerability findings from the first multinational Phase I/II clinical trial evaluating ibrilatazar in children and adolescents with relapsed or treatment-resistant solid tumours. The paper summarises the trial design, the paediatric dose-finding approach and the early signals observed across the first cohorts of patients enrolled at centres across Europe, and discusses what these results mean for the next phase of the study and for future paediatric oncology research.